Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM16RIC)

• Drug Name: Oprozomib Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hodgkin lymphoma	2B30	Phase 2	[1]
Haematological malignancy	2B33.Y	Phase 1/2	[2]
Multiple myeloma	2A83	Phase 1	[3]
Solid tumour/cancer	2A00-2F9Z	Preclinical	[4]

• Cross-matching ID:
  PubChem CID: 25067547
  CAS Number: CAS 935888-69-0
  TTD Drug ID: DM16RIC

Molecule-Related Drug Atlas

Drug(s) Targeting Proteasome (PS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[6]
MLN9708	DMCMETN	Amyloidosis	5D00	Approved	[7]
Carfilzomib	DM48K0X	Multiple myeloma	2A83	Approved	[8]
Marizomib	DME9QGW	Glioblastoma of brain	2A00.00	Phase 3	[9]
Delanzomib	DMX4DQH	Multiple myeloma	2A83	Phase 2	[10]
GSK3494245	DMSMQGL	Visceral leishmaniasis	1F54.0	Phase 1	[11]
PS-519	DMI0WHC	Ischemia-reperfusion injury	DB98.B	Terminated	[12]
MG-101	DM3RUT8	Discovery agent	N.A.	Investigative	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proteasome (PS)	TTU7ZMG	NOUNIPROTAC	Modulator	[5]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT01832727) Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027317)
• [5] A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 2;116(23):4906-15.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80.
• [8] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [9] Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.
• [10] Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [12] Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in... Neurotox Res. 2003;5(7):505-14.
• [13] Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study.J Mol Model.2009 Dec;15(12):1481-90.